Clinical Trial

Perspectives of Italian Employers Regarding the Return to Work Process of Employees Who Received a Cancer Diagnosis: a Qualitative Study

Study acronym: employers_2024
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 29, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
European Cancer Mission calls attention to the return to work (RTW) of cancer survivors (CSs), as one of the pivotal issues of the cancer continuum that need to be addressed through proper and prompt actions and recommendations. Employers are important stakeholders, as they can provide emotional and practical support, sustain communication during the entire process, and guarantee a gradual work reintegration. In Italy there is lack of knowledge regarding this topic. Thus, further exploration of Italian employers' perspectives on the RTW of employees with cancer should be performed to comprehend their unknown experiences. The aim is to explore the perspectives of employers who dealt with the RTW process of employees who received a cancer diagnosis through a qualitative research design.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-20; most recent amendment 2025-08-28.
Status change: Not Yet Recruiting → Recruiting 2025-08-28
Trial Details
NCT Number NCT06994182
Lead Sponsor Azienda USL Reggio Emilia - IRCCS
Collaborators: Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)
Conditions Cancer Survivors
Enrollment 30 participants
Start Date 2025-04-01
Primary Completion 2026-06 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2025-08-29